146 related articles for article (PubMed ID: 8460127)
1. Polymerization of murine macrophage inflammatory protein 1 alpha inactivates its myelosuppressive effects in vitro: the active form is a monomer.
Mantel C; Kim YJ; Cooper S; Kwon B; Broxmeyer HE
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2232-6. PubMed ID: 8460127
[TBL] [Abstract][Full Text] [Related]
2. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha.
Cooper S; Mantel C; Broxmeyer HE
Exp Hematol; 1994 Feb; 22(2):186-93. PubMed ID: 8299739
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression.
Broxmeyer HE; Sherry B; Cooper S; Lu L; Maze R; Beckmann MP; Cerami A; Ralph P
J Immunol; 1993 Apr; 150(8 Pt 1):3448-58. PubMed ID: 7682242
[TBL] [Abstract][Full Text] [Related]
4. Macrophage inflammatory protein (MIP)-1 beta abrogates the capacity of MIP-1 alpha to suppress myeloid progenitor cell growth.
Broxmeyer HE; Sherry B; Cooper S; Ruscetti FW; Williams DE; Arosio P; Kwon BS; Cerami A
J Immunol; 1991 Oct; 147(8):2586-94. PubMed ID: 1918979
[TBL] [Abstract][Full Text] [Related]
5. Myelosuppressive effects in vivo of purified recombinant murine macrophage inflammatory protein-1 alpha.
Maze R; Sherry B; Kwon BS; Cerami A; Broxmeyer HE
J Immunol; 1992 Aug; 149(3):1004-9. PubMed ID: 1634758
[TBL] [Abstract][Full Text] [Related]
6. Distinct and overlapping direct effects of macrophage inflammatory protein-1 alpha and transforming growth factor beta on hematopoietic progenitor/stem cell growth.
Keller JR; Bartelmez SH; Sitnicka E; Ruscetti FW; Ortiz M; Gooya JM; Jacobsen SE
Blood; 1994 Oct; 84(7):2175-81. PubMed ID: 7919333
[TBL] [Abstract][Full Text] [Related]
7. Macrophage inflammatory protein-1 alpha enhances growth factor-stimulated phosphatidylcholine metabolism and increases cAMP levels in the human growth factor-dependent cell line M07e, events associated with growth suppression.
Mantel C; Aronica S; Luo Z; Marshall MS; Kim YJ; Cooper S; Hague N; Broxmeyer HE
J Immunol; 1995 Mar; 154(5):2342-50. PubMed ID: 7532666
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha.
Ferrajoli A; Talpaz M; Zipf TF; Hirsch-Ginsberg C; Estey E; Wolpe SD; Estrov Z
Leukemia; 1994 May; 8(5):798-805. PubMed ID: 8182937
[TBL] [Abstract][Full Text] [Related]
9. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells.
Eaves CJ; Cashman JD; Wolpe SD; Eaves AC
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):12015-9. PubMed ID: 8265663
[TBL] [Abstract][Full Text] [Related]
10. The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism.
Cashman JD; Eaves AC; Eaves CJ
Blood; 1994 Sep; 84(5):1534-42. PubMed ID: 8068944
[TBL] [Abstract][Full Text] [Related]
11. Interferon-inducible protein 10 and macrophage inflammatory protein-1 alpha inhibit growth factor stimulation of Raf-1 kinase activity and protein synthesis in a human growth factor-dependent hematopoietic cell line.
Aronica SM; Mantel C; Gonin R; Marshall MS; Sarris A; Cooper S; Hague N; Zhang XF; Broxmeyer HE
J Biol Chem; 1995 Sep; 270(37):21998-2007. PubMed ID: 7545174
[TBL] [Abstract][Full Text] [Related]
12. Biological and structural properties of MIP-1 alpha expressed in yeast.
Clements JM; Craig S; Gearing AJ; Hunter MG; Heyworth CM; Dexter TM; Lord BI
Cytokine; 1992 Jan; 4(1):76-82. PubMed ID: 1617159
[TBL] [Abstract][Full Text] [Related]
13. BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.
Hunter MG; Bawden L; Brotherton D; Craig S; Cribbes S; Czaplewski LG; Dexter TM; Drummond AH; Gearing AH; Heyworth CM; Lord BI; McCourt M; Varley PG; Wood LM; Edwards RM; Lewis PJ
Blood; 1995 Dec; 86(12):4400-8. PubMed ID: 8541527
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta: is it a downregulator of stem cell inhibition by macrophage inflammatory protein 1 alpha?
Maltman J; Pragnell IB; Graham GJ
J Exp Med; 1993 Sep; 178(3):925-32. PubMed ID: 8394405
[TBL] [Abstract][Full Text] [Related]
15. A novel chemokine, macrophage inflammatory protein-related protein-2, inhibits colony formation of bone marrow myeloid progenitors.
Youn BS; Jang IK; Broxmeyer HE; Cooper S; Jenkins NA; Gilbert DJ; Copeland NG; Elick TA; Fraser MJ; Kwon BS
J Immunol; 1995 Sep; 155(5):2661-7. PubMed ID: 7650394
[TBL] [Abstract][Full Text] [Related]
16. Aggregation of the chemokine MIP-1 alpha is a dynamic and reversible phenomenon. Biochemical and biological analyses.
Graham GJ; MacKenzie J; Lowe S; Tsang ML; Weatherbee JA; Issacson A; Medicherla J; Fang F; Wilkinson PC; Pragnell IB
J Biol Chem; 1994 Feb; 269(7):4974-8. PubMed ID: 8106472
[TBL] [Abstract][Full Text] [Related]
17. Contrasting effects of rh-MIP-1 alpha and TGF-beta 1 on chronic myeloid leukemia progenitors in vitro.
Holyoake TL; Freshney MG; Sproul AM; Richmond LJ; Alcorn MJ; Steward WP; Fitzsimons E; Dunlop DJ; Franklin IM; Pragnell IB
Stem Cells; 1993 Oct; 11 Suppl 3():122-8. PubMed ID: 8298472
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo.
Lord BI; Dexter TM; Clements JM; Hunter MA; Gearing AJ
Blood; 1992 May; 79(10):2605-9. PubMed ID: 1586712
[TBL] [Abstract][Full Text] [Related]
19. Macrophage inflammatory protein-1 alpha receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia.
Chasty RC; Lucas GS; Owen-Lynch PJ; Pierce A; Whetton AD
Blood; 1995 Dec; 86(11):4270-7. PubMed ID: 7492787
[TBL] [Abstract][Full Text] [Related]
20. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.
Broxmeyer HE; Orazi A; Hague NL; Sledge GW; Rasmussen H; Gordon MS
Blood Cells Mol Dis; 1998 Mar; 24(1):14-30. PubMed ID: 9516378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
